title: Mooren's-type ulceration associated with severe hidradenitis suppurativa: a case report and literature review.
abstract: OBJECTIVE
  To report a case of bilateral Mooren's-type corneal ulcers associated with severe hidradenitis suppurativa.
  
  
  METHODS
  Case report and literature review.
  
  
  METHODS
  Detailed clinical course including presentation, medical, and surgical treatment.
  
  
  RESULTS
  A 47-year-old African American male with severe hidradenitis suppurativa presented with bilateral Mooren's-type corneal ulcers. His systemic workup was unrevealing. Progression led to bilateral corneal perforations. Systemic immunosuppression and surgical intervention were needed to control his disease.
  
  
  CONCLUSIONS
  Severe hidradenitis suppurativa should be considered as a risk factor for Mooren's-type corneal ulcer.
authors.affiliation: Eye Physicians & Surgeons PC, 202 Cherry Street, Milford, CT 06460, USA. swmeskin@yahoo.com
authors.forename: Seth W
authors.initials: SW
authors.lastname: Meskin
authors.forename: Elise M
authors.initials: EM
authors.lastname: Carlson
mesh_terms: D000650:Amnion / Q000637:transplantation; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001372:Aza Compounds / Q000627:therapeutic use; D003228:Conjunctiva / Q000601:surgery; D057112:Corneal Perforation / Q000601:surgery; D003320:Corneal Ulcer / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery; D003879:Dermatologic Agents / Q000627:therapeutic use; D018450:Disease Progression; D004318:Doxycycline / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones; D017497:Hidradenitis Suppurativa / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D000077266:Moxifloxacin; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D000911:Antibodies, Monoclonal; D001372:Aza Compounds; D003879:Dermatologic Agents; D024841:Fluoroquinolones; D007166:Immunosuppressive Agents; D011804:Quinolines; D011239:Prednisolone; D000069285:Infliximab; D004318:Doxycycline; D000077266:Moxifloxacin; D011241:Prednisone; D008727:Methotrexate